Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study

Documenti analoghi

• Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA
  di: Shunsuke Yamada, et al.
  Pubblicazione: (2024)
• Correction to “Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA”
  Pubblicazione: (2025)
• Kinetics of the hepatitis B core‐related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide
  di: Norio Itokawa, et al.
  Pubblicazione: (2024)
• Letter: Risk Prediction Model for HCC in Subjects Without Apparent Chronic Liver Disease: A Dilemma in Asia. Author's Reply
  di: Byeong Geun Song, et al.
  Pubblicazione: (2025)
• Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance
  di: Han Ah. Lee, et al.
  Pubblicazione: (2025)